Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Popoli

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Recenti Progressi in Medicina|December 20, 2021
[The regulatory evaluation of tumor-agnostic drugs.]Patrizia Popoli
Current Pharmaceutical Design|June 10, 2008
Regulation of brain functions by A2A receptors: implication for therapeuticsPatrizia Popoli
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
New challenges in translational medicine: transforming the advancement of science into cures. PrefaceEnrico Garaci, Patrizia Popoli
CNS & Neurological Disorders Drug Targets|September 12, 2012
Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous systemPatrizia Popoli, Rita Pepponi
Brain Research|May 9, 2012
Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmissionMaria Teresa Tebano, Alberto Martire, Patrizia Popoli
International Journal of Molecular Sciences|February 10, 2024
Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative ReviewRosa Luisa Potenza, Monica Armida, Patrizia Popoli
Global & Regional Health Technology Assessment|June 21, 2024
Patrizia Popoli, Giovanni Giuliani, Arturo Cavaliere, et al.
European Journal of Pharmacology|September 5, 2002
SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slicesMaria Teresa Tebano, Maria Rosaria Domenici, Patrizia Popoli
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapiesPatrizia Popoli, Maria Francesca Cometa, Fulvia Fabi, et al.
Frontiers in Pharmacology|March 8, 2021
P2X7 Receptor Agonist 2'(3')-O-(4-Benzoylbenzoyl)ATP Differently Modulates Cell Viability and Corticostriatal Synaptic Transmission in Experimental Models of Huntington's DiseaseAlberto Martire, Rita Pepponi, Francesco Liguori, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Recenti Progressi in Medicina|December 20, 2021
[The regulatory evaluation of tumor-agnostic drugs.]Patrizia Popoli
Current Pharmaceutical Design|June 10, 2008
Regulation of brain functions by A2A receptors: implication for therapeuticsPatrizia Popoli
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
New challenges in translational medicine: transforming the advancement of science into cures. PrefaceEnrico Garaci, Patrizia Popoli
CNS & Neurological Disorders Drug Targets|September 12, 2012
Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous systemPatrizia Popoli, Rita Pepponi
Brain Research|May 9, 2012
Adenosine A(2A)-cannabinoid CB(1) receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmissionMaria Teresa Tebano, Alberto Martire, Patrizia Popoli
International Journal of Molecular Sciences|February 10, 2024
Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative ReviewRosa Luisa Potenza, Monica Armida, Patrizia Popoli
Global & Regional Health Technology Assessment|June 21, 2024
Patrizia Popoli, Giovanni Giuliani, Arturo Cavaliere, et al.
European Journal of Pharmacology|September 5, 2002
SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slicesMaria Teresa Tebano, Maria Rosaria Domenici, Patrizia Popoli
Annali Dell'Istituto Superiore Di Sanita|March 25, 2011
The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapiesPatrizia Popoli, Maria Francesca Cometa, Fulvia Fabi, et al.
Frontiers in Pharmacology|March 8, 2021
P2X7 Receptor Agonist 2'(3')-O-(4-Benzoylbenzoyl)ATP Differently Modulates Cell Viability and Corticostriatal Synaptic Transmission in Experimental Models of Huntington's DiseaseAlberto Martire, Rita Pepponi, Francesco Liguori, et al.
Pageof 10